Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.

myTempleHealth
SEARCH TEMPLE HEALTH
Lung Center

The Temple Lung Center at ATS 2024

Follow Temple faculty and fellows as they present at this year’s American Thoracic Society (ATS) International Conference.

May 17 - 22 | San Diego, California

Jump to:

Authorities in the field, including internationally renowned pulmonologist Gerard J. Criner, MD, board member for the Global Initiative for Chronic Obstructive Lung Disease (GOLD), an author of the GOLD guidelines, and Director of the Temple Lung Center in Philadelphia, PA presented at the following sessions:

Saturday, May 18, 2024

2024 ATS-APCCMPD-PEPTDA Forum for Clinical Educators

1:00 – 4:00 pm PT

Innovations of the year award: Temple University Hospital

TextBytes for Smarter Practice: Revolutionizing Tobacco Use Disorder Treatment Education for Physicians
Zehra Dhanani, Veena Dronamraju, Jamie Garfield

Sunday, May 19, 2024

Session A26: IMPROVING OUTCOMES IN SARCOIDOSIS, RARE LUNG DISEASE AND LUNG TRANSPLANT

TIME: 9:15 AM – 11:15 AM

New and Old Definitions of Pre-capillary and Severe Pulmonary Hypertension: Predicting Mortality in Sarcoidosis Associated Pulmonary Hypertension
T. Russeth, O. Schanz, P. Rali, G. J. Criner, S. Gayen


Session A27: EMERGING TREATMENTS AND THERAPEUTIC STRATEGIES IN COPD: RESULTS OF CLINICAL TRIALS AND OBSERVATIONAL STUDIES

TIME: 9:15 AM – 11:15 AM

Impact of Biologics on Exacerbation Burden and Pulmonary Function Tests in Patients With COPD and ACOS: A Real-world, Single-center Review
S. Dachert, T. A. Ho, I. Albaba, S. Ansari, N. Provenzano, J. Halicki, G. J. Criner

Efficacy of Mepolizumab in Patients With COPD and an Eosinophilic Phenotype With Chronic Bronchitis - A Post Hoc Analysis of the METREX & METREO Phase 3 Studies
G. J. Criner, N. A. Hanania, F. Maltais, F. Martinez, M. Bafadhel, H. Watz, D. Singh, R. Chan, S. Kolterer, B. Mayer

Bronchoscopic Lung Volume Reduction With Zephyr Endobronchial Valves Improves Lung Function and Symptoms in Chronic Obstructive Pulmonary Disease Patients With Alpha-1 Antitrypsin Deficiency
M. Nicholson, G. J. Criner

Bronchial Rheoplasty Reduces Mucus Plugging in Patients with Chronic Bronchitis
V. Kim, W. S. Krimsky


Session A45: VARIETY IS THE SPICE OF LIFE: CRITICAL CARE CASE REPORT POTPOURRI

TIME: 11:30 AM – 1:15 PM

Large Pericardial Cyst in a Lung Transplant Patient
K. H. Patel, J. Halicki, S. Dachert, A. Mamary


Session A47: ILD OUTCOMES

TIME: 11:30 AM – 1:15 PM

Post-operative Outcomes in Patients With Pulmonary Sarcoidosis in Relation to Lung Explant Pathology
I. Tsai, J. Kim, M. Zheng, A. Aneja, M. Kumaran, A. L. Johnson Whiting, R. Criner, B. H. Lashari, F. Anjum, N. Marchetti, K. V. Shenoy, A. J. Mamary, F. C. Cordova, N. Shigemura, G. J. Criner, R. Gupta

How the 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines Affect Our Understanding of Mortality in Non-IPF ILD
I. Tsai, O. Schanz, P. Rali, G. J. Criner, S. Gayen


Session A48: COPD EXACERBATIONS AND HOSPITALIZATIONS: DETERMINANTS AND DRIVERS

TIME: 11:30 AM – 1:15 PM

Impact of COPD Exacerbations and CT-Emphysema on Presence of Pleural Adhesions in Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS) Lung Resection
A. Gulzar, N. Marchetti, C. Bakhos, G. J. Criner


Session A50: ALL ABOUT EFFUSIONS: BILE, CHYLE, URINE, PANCREATIC FLUID, AND OTHER RARE CASE REPORTS

TIME: 11:30 AM – 1:15 PM

Left-Side Mystery: Unusual Cause of Chest Fluid - A Case Report
Z. Dhanani, G. J. Criner


Session A55: MEDICAL MAYHEM: CASE REPORTS OF LUNG INJURY IN VAPING, MARIJUANA, AND COCAINE USE

TIME: 11:30 AM – 1:15 PM

A Rare Case of a Bronchocutaneous Fistula After Xylazine Use
J. Kim, I. Tsai, M. Kumaran, R. Gupta


Session A58: EXPANDING OUR RE(PERT)OIRES IN SAN DIEGO: NOVEL CLINICAL DISCOVERIES IN PULMONARY EMBOLISM

TIME: 11:30 AM – 1:15 PM

Prognostic Value of Tricuspid Annular Plan Systolic Excursion/Right Ventricular Systolic Pressure Ratio in Acute Pulmonary Embolism
K. Santerian, K. U. Lio, B. Rivera-Lebron, S. Brosnahan, P. Rali

Predictors of Residual Pulmonary Vascular Obstruction After Acute Pulmonary Embolism Based on Patient Variables and Treatment Modality
T. A. Ho, J. M. Pescatore, K. U. Lio, G. J. Criner, P. Rali, S. Gayen
S. Ansari, A. B. Karanam, S. Gayen, P. Rali, G. J. Criner


Session A72: EPITHELIAL CELLS: KEY CULPRITS IN PULMONARY FIBROSIS

TIME: 11:30 AM – 1:15 PM

Impaired DNA Damage Repair in Alveolar Type II Cells in Idiopathic Pulmonary Fibrosis
K. Bahmed, C. Lin, L. Karim, S. Bolla, N. Marchetti, G. J. Criner, B. Kosmider


Session A76: ASSESSING RISKS AND OUTCOMES IN INTERSTITIAL LUNG DISEASE

TIME: 11:30 AM – 1:15 PM

Impact of Revised ESC Pulmonary Hypertension Criteria on Lung Transplantation Waitlist Outcomes in Idiopathic Pulmonary Fibrosis Patients
Z. Dhanani, M. Nicholson, S. Gayen

Impaired DNA Damage Repair in Alveolar Type II Cells in Idiopathic Pulmonary Fibrosis
K. Bahmed, C. Lin, L. Karim, S. Bolla, N. Marchetti, G. J. Criner, B. Kosmider


Meet the Expert, MTE4: NAVIGATING THE EVOLVING THERAPEUTICS IN MANAGEMENT OF PULMONARY SARCOIDOSIS

TIME: 11:30 AM – 12:30 PM

Treatment of sarcoidosis remains challenging, but the field has been evolving faster recently with new agents in development. This session focuses on individualization of therapy, discusses the general principles in use of different drugs in clinical practice and an insight into the new agents in pipeline for sarcoidosis.
Rohit Gupta, MD, MBBS


Session A103: DYSREGULATED PATHWAYS IN SEPSIS AND LUNG INJURY: SEARCHING FOR TREATABLE TRAITS

TIME: 2:15 PM – 4:15 PM

Distinct Neutrophil Phenotypes in Sepsis Patients and Associations With Disease Severity, Comorbidities, and Neutrophil Extracellular Traps (NETs)
S. Pettigrew, R. Prosniak, Q. Yang, J. Langston, E. Perez, H. Edelmann, N. Mansoor, N. Marchetti1, M. Kiani, L. Kilpatrick


Session A107: INFECTIONS IN THE IMMUNOSUPPRESSED AND IMMUNOCOMPROMISED HOST

TIME: 2:15 PM – 4:15 PM

Role of Fungal Colonization in the Development of Chronic Lung Allograft Dysfunction
Z. Dhanani, G. J. Criner, F. Anjum

Back to top >

Monday, May 20, 2024

Session B21: RESEARCH STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE

TIME: 9:15 AM - 11:15 AM

Outcomes of Bronchoscopic Lung Volume Reduction in Patients With Static and Dynamic Hyperinflation
A. B. Karanam, M. Reeves, J. Thomas, G. J. Criner


Session B47: LUNG TRANSPLANT

TIME: 11:30 AM – 1:15 PM

Navigating Airway Challenges After Lung Transplantation
Z. Dhanani, G. J. Criner, F. Anjum

Preoperative Anemia as a Risk Factor for Post Operative Outcomes in Patients Undergoing Lung Transplant
J. Galvis, T. A. Ho, O. Schanz, T. Russeth, H. Zhao, J. Armstrong, J. Mamary

The Prevalence and Evaluation of Anemia in Lung Transplant Recipients: A Single Center Experience
T. A. Ho, J. Galvis, M. Goulet, T. Joshi, H. Zhao, J. Armstrong, A. J. Mamary


Session B48: NEW TREATMENTS IN DIFFUSE PARENCHYMAL LUNG DISEASE

TIME: 11:30 AM – 1:15 PM

Pulmonary Vasodilator Therapy in Idiopathic Pulmonary Fibrosis Associated Pulmonary Hypertension
R. Strock, O. A. Schanz, P. Rali, G. J. Criner, S. Gayen


Session B50: EMERGING RESEARCH IN ALPHA-1-ANTITRYPSIN DEFICIENCY

TIME: 11:30 AM – 1:15 PM

Effectiveness of Bronchoscopic Lung Volume Reduction With Zephyr Endobronchial Valves in Alpha-1 Antitrypsin Deficient Chronic Obstructive Pulmonary Disease Patients Versus Chronic Obstructive Pulmonary Disease Patients Without Alpha-1 Antitrypsin Deficiency: A Matched Case-control Study
M. Nicholson, G. J. Criner


Session B52: EVIDENCE FOR THERAPEUTIC STRATEGIES IN COPD: FROM ESTABLISHED TO EMERGING

TIME: 11:30 AM – 1:15 PM

Impact of Biologics in Patients With COPD and ACOS: A Real-world, Single-center Review of Factors Associated With Greater Reduction in Exacerbation Frequency
S. Dachert, T. A. Ho, I. Albaba, S. Ansari, N. Provenzano, J. Halicki, G. J. Criner

Ensifentrine Added on to LABA/ICS Therapy Improved Lung Function and Reduced Exacerbations in Symptomatic Subjects With Moderate-to-Severe COPD
N. Marchetti, R. Kalhan, M. T. Dransfield, A. Anzueto, T. Rheault, D. Reyner, T. Bengtsson, K. Rickard

Targeted Lung Denervation in COPD: 2-year Follow-up of the Airflow-3 Open-label Treatment Cohort
G. J. Criner, F. C. Sciurba, D.-J. Slebos, S. P. Bhatt, C. Ghattas, B. Petkovich, J. De Cardenas, C. R. Lamb, R. D. Sue, P. L. Shah


Session B59: DEFINING DISPARITIES IN PULMONARY VASCULAR DISEASES

TIME: 11:30 AM – 1:15 PM

Disparity in Pulmonary Embolism Outcomes Amongst Asians
A. Mittal, S. Li2, T. A. Ho, M. Yaqoob, P. Rali


Session B60: CYANOTIC PACIFIC BLUE: GROUP 3 PH AND HYPOXIC LUNG DISEASE

TIME: 11:30 AM – 1:15 PM

Prognostic Limitations for Who Group 3 Pulmonary Hypertension Patients - A Retrospective Study
M. J. Bittner, J. M. Pescatore, S. E. Weaver, S. Gayen

Clinical Significance of Updated Pulmonary Hypertension Guidelines on Combined Pulmonary Fibrosis and Emphysema (CPFE)
J. Moore, P. Rali, S. Gayen

New European Society of Cardiology Definition of Severe Pulmonary Hypertension Predicts Mortality in Patients With Idiopathic Pulmonary Fibrosis
A. Kurtzman, P. Rali, G. J. Criner, S. Gayen

Pulmonary Vasodilatory Therapy in Patients With Chronic Obstructive Pulmonary Disease-mediated Pulmonary Hypertension
A. Chung, P. Rali, G. J. Criner, S. Gayen

ILD/CPFE With Severe WHO Group III PH Patients Referred to Transplant Center for Evaluation: An Observational Study
J. M. Pescatore, M. Bitter, S. E. Weaver

Effect of Updated European Society of Cardiology Pulmonary Hypertension Diagnostic Criteria on Lung Transplantation Waitlist Outcomes in Hypersensitivity Pneumonitis Patients Listed for Lung Transplantation
M. Nicholson, Z. Dhanani, S. Gayen

Effect of Pulmonary Vasodilator Therapy on Survival and Functional Outcomes in Patient With Combined Pulmonary Fibrosis and Emphysema and Pulmonary Hypertension
O. A. Schanz, I. Tsai, J. Moore, T. Joshi, A. Chung, R. Strock, A. Kurtzman, T. Russeth, K. Johnson, J. Galvis, S. Gayen


Session B61: THE NEED FOR SPEED: ARTIFICIAL INTELLIGENCE IN PVD

TIME: 11:30 AM – 1:15 PM

AI-driven PE Detection and RV/LV Ratio Measurement: A Preliminary Validation Study
Z. Dhanani, K. U. Lio, T. Joshi, P. Rali

Real World Assessment of Artificial Intelligence for Pulmonary Embolism Detection and Risk Stratification
S. Pettigrew, J. Nathan, K. Maruti, G. Cohen, G. J. Criner, P. Rali


Session B70: COPD IN THE SPOTLIGHT: INSIGHTS INTO DISEASE PATHOGENESIS

TIME: 11:30 AM – 1:15 PM

S100A8-MCM3 Axis in Alveolar Type II Cells in Emphysema
K. Bahmed, C. Lin, S. Bolla, N. Marchetti, G. J. Criner, B. Kosmider


Session B80-2: ABNORMALITIES IN STRUCTURE AND FUNCTION IN COPD

TIME: 11:30 AM – 1:15 PM

Change in Pulmonary Artery: Aorta Ratio (PA:A) in Patients Undergoing Bronchoscopic Lung Volume Reduction Surgery (BLVR) Vs Lung Volume Reduction Surgery (LVRS)
S. Ansari, S. Dachert, S. Gayen, J. Thomas, H. Zhao, C. Dass, G. J. Criner

Predictors of Dynamic Hyperinflation in Advanced Chronic Obstructive Pulmonary Disease
A. B. Karanam, J. Thomas, G. J. Criner

Back to top >

Tuesday, May 21, 2024

C29: ADVANCED LUNG IMAGING; THE PULMONARY PAPARAZZI

TIME: 9:15 AM – 11:15 AM

AI Assisted Lung Texture Analysis Association With Lung Rads Score in an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)
S. Dachert, M. A. Seigo, O. Ahearn, G. J. Criner

Relationship Between AI Assisted Lung Texture Analysis and Pulmonary Function Testing in an Urban Comprehensive Lung Cancer Screening Program for Lung Nodules Coupled With Detection of Comorbid Conditions: Temple Healthy Chest Initiative (THCI)
S. Dachert, M. A. Seigo, O. Ahearn, G. J. Criner


Session C34: BIOLOGIC THERAPY IN THE FIGHT AGAINST ASTHMA AND ALLERGIC INFLAMMATION

TIME: 11:30 AM – 1:15 PM

Safety Profile of Astegolimab, An Anti-ST2 Antibody: A Systematic Review
S. G. Kelsen, G. Alvaro, L. Millette, D. Mohan, X. Yang, C. E. Brightling


Session C42: ALL ABOUT THE AIRWAYS AND ALVEOLI: RESPIRATORY FAILURE CASE REPORTS

TIME: 11:30 AM – 1:15 PM

Near Complete Disruption of the Right Mainstem Bronchus After Blunt Thoracic Trauma
D. Potarazu, S. B. Peer, P. Ferrada


Session C46: CLINICAL AND PHYSIOLOGIC METRICS OF RESPIRATORY DISEASE AND COPD: FROM DIAGNOSIS TO PROGNOSIS

TIME: 11:30 AM – 1:15 PM

Prevalence of Spirometric Obstruction and Undiagnosed COPD in Lung Cancer Screening Cohorts: A Systematic Review and Meta-analysis
S. Dachert, M. A. Seigo, M. E. Zulty, G. J. Criner


Session C55: COMORBIDITIES OF COPD: EPIDEMIOLOGY AND TREATMENT IMPLICATIONS

TIME: 11:30 AM – 1:15 PM

New 2022 ESC/ERS Severe Pulmonary Hypertension Definition Better Predicts Mortality in Patients With COPD
T. Joshi, S. Olivia2, G. J. Criner2, P. Rali2, S. Gayen

Pulmonary Comorbidities, Respiratory Symptoms, and Spirometry in a Real-world, Urban Lung Cancer Screening Program
M. A. Seigo, S. Dachert, A. B. Karanam, G. J. Criner


Session C78: WHAT'S THAT? ATYPICAL AND RARE PRESENTATIONS IN THORACIC ONCOLOGY

TIME: 11:30 AM – 1:15 PM

Primary Pulmonary Biphasic Synovial Sarcoma - A Case Report
B. Y. Graham, A. Padmanabhan


Session C81: CURRENT AND EVOLVING STRATEGIES FOR MANAGEMENT OF PULMONARY SARCOIDOSIS

TIME: 2:15 PM – 3:45 PM

Chairs: Rohit Gupta, MD, MBBS and Jin Sun Kim, MD

Discussion on current understanding of (and knowledge gaps in) disease mechanisms, recent advances in management and ongoing/ future research endeavors on pulmonary sarcoidosis and APS.

Dr. Gupta will present on Lung Transplantation and Holistic Care in APS.


Session C103: DISPARITIES AND SOCIAL DETERMINANTS OF HEALTH IN PULMONARY, CRITICAL CARE, AND SLEEP MEDICINE

TIME: 2:15 PM – 4:15 PM

Trends and Racial Disparities in Pulmonary Embolism Admissions From 2017 to 2023
A. Mittal, S. Li, T. A. Ho, P. Rali


C104: BLEEDING AND CLOTTING AND EMBOLI, OH MY! HEMATOLOGIC CASES IN THE ICU

TIME: 2:15 PM – 4:15 PM

Pulmonary Embolism With Trauma-Associated Thrombotic Microangiopathy
J. Ayyoub, M. A. Seigo, P. Rali, A. Ajmeri


Session C110: SURFING THE INNOVATION WAVE IN SAN DIEGO: CUTTING-EDGE LUNG CANCER BIOMARKERS, DIAGNOSTICS AND TREATMENTS

TIME: 2:15 PM – 4:15 PM

Neoadjuvant Soft Tissue Ablation Utilizing Aliya™ Pulsed Electric Fields With Systemic Therapy in Early-stage Resectable Non-small Cell Lung Cancer (NSCLC) - VIGOR Study
J. Reisenauer, D. Dibardino, G. J. Criner, M. Callstrom, S. Hunt, J. Panero, W. S. Krimsky

Back to top >

Wednesday, May 22, 2024

Session D24: IF IT QUACKS LIKE A ZEBRA: INTERESTING CASE REPORTS IN DIFFUSE PARENCHYMAL LUNG DISEASE

TIME: 8:15 AM – 10:15 AM

Plastic Bronchitis as a Complication of Primary Graft Dysfunction After Single Lung Transplantation
M. A. Seigo, J. Ayyoub, J. M. Pescatore, S. Dachert, G. D'Alonzo


Session D109: NOW WE GOT BAD BLOOD: RSF/PC JOINT SESSION ON PULMONARY VASCULAR DISEASE

TIME: 11:00 AM – 1:00 PM

Thrombus In Situ Unveiled: Distinguishing Pulmonary Artery Thrombosis From Pulmonary Embolism
Z. Dhanani, C. Edward, B. H. Lashari, M. Kumaran


Session D105: BALBOA PARK EXPLORERS: TRANSLATIONAL SCIENCE AND EPIDEMIOLOGY IN PH

TIME: 11:00 AM – 1:00 PM

Applying the New Definition of Pulmonary Hypertension to Patients With Idiopathic Pulmonary Fibrosis on the Transplant Waitlist, A Registry Review
M. E. Zulty, G. J. Criner, S. Gayen


Session D110: PUZZLING PRESENTATIONS AND COMPLEX DIAGNOSES: NAVIGATING THE DIVERSE LANDSCAPE OF THORACIC ONCOLOGY

TIME: 11:00 AM – 1:00 PM

A Rare Case of Primary Lung Synovial Sarcoma With Squamous Differentiation and a Novel FOXL2 Mutation in an Older Patient
A. B. Karanam, M. E. Zulty, G. E. D Alonzo, J. Friedberg, M. F. Gonzalez

Back to top >